The global gastroenterology market size is likely to be valued at US$40.2 billion in 2026 and is expected to reach US$62.5 billion by 2033, growing at a CAGR of 6.5% during the forecast period from 2026 to 2033, driven by the increasing prevalence of gastrointestinal disorders, rising demand for advanced diagnostic procedures, and expanding adoption of biologics and targeted therapies for digestive diseases.

The market is supported by growing awareness of early disease detection, technological advancements in endoscopy, and increasing healthcare investments across developed and emerging economies. According to the World Health Organization (WHO), colorectal cancer accounted for approximately 1.9 million new cases and more than 900,000 deaths globally in 2024, making it the third most common cancer and second leading cause of cancer-related deaths worldwide. Population aging, changing dietary habits, obesity, and sedentary lifestyles continue to elevate the burden of gastrointestinal diseases.

Driver - Rising Prevalence of GI Disorders and Aging Population

Conditions such as inflammatory bowel disease, gastroesophageal reflux disease, irritable bowel syndrome, colorectal cancer, and chronic liver diseases are becoming more common due to sedentary lifestyles, unhealthy dietary habits, obesity, smoking, and alcohol consumption. Growing awareness of digestive health and improved access to healthcare services have led to higher diagnosis rates, increasing demand for gastroenterology treatments and procedures.

Healthcare providers are expanding screening programs and preventive care initiatives, supporting market growth through earlier detection and long-term management of gastrointestinal conditions. Population aging is another major factor accelerating demand across the gastroenterology market. Older adults are more susceptible to digestive disorders, gastrointestinal cancers, motility disorders, and chronic inflammatory conditions that require continuous monitoring and treatment.

As life expectancy increases across developed and emerging economies, healthcare systems are witnessing a greater burden of age-related gastrointestinal diseases. This trend supports demand for advanced endoscopic procedures, biologic therapies, minimally invasive interventions, and specialized gastroenterology services. Pharmaceutical companies and healthcare providers are increasingly focusing on age-specific treatment approaches.

Restraint - Shortage of Skilled Professionals

Gastroenterology relies heavily on trained endoscopists, surgeons, nurses, and technicians to conduct complex interventions and manage chronic digestive disorders. Many healthcare systems face workforce limitations due to lengthy training requirements, increasing patient volumes, and uneven distribution of specialists between urban and rural areas. These shortages result in longer waiting times for diagnosis and treatment, reducing patient access to timely care and limiting the adoption of advanced gastroenterology technologies in various healthcare settings.

The challenge is particularly evident in developing regions where healthcare infrastructure and specialist training programs remain limited. Hospitals and clinics frequently struggle to recruit and retain qualified gastroenterology professionals, affecting operational efficiency and service quality. Advanced technologies such as AI-assisted endoscopy and complex therapeutic procedures require additional expertise, creating workforce demands. Limited availability of trained personnel can slow the implementation of innovative treatment approaches and increase healthcare costs associated with specialist care.

Opportunity - Technological Convergence and Personalized Medicine

Technological convergence is creating substantial opportunities within the gastroenterology market by integrating advanced diagnostics, artificial intelligence, digital health platforms, and minimally invasive therapeutic solutions. AI-powered endoscopy systems are improving lesion detection accuracy, supporting earlier diagnosis of gastrointestinal diseases, and enhancing procedural efficiency.

Innovations in imaging technologies, capsule endoscopy, robotic-assisted procedures, and real-time data analytics are transforming patient management and clinical decision-making. These advancements help physicians deliver more precise and efficient care while improving patient outcomes. As healthcare providers continue investing in digital transformation initiatives, technology-driven solutions are expected to play an increasingly important role in gastroenterology practice.

Personalized medicine represents another major growth opportunity, particularly for patients with chronic inflammatory and autoimmune gastrointestinal disorders. Advances in molecular diagnostics, biomarker identification, and genetic profiling enable healthcare professionals to tailor treatment strategies according to individual patient characteristics. This approach improves therapeutic effectiveness while reducing unnecessary treatment costs and adverse effects.

Drug Type Insights

Biologics/biosimilars are expected to account for 32% of revenue in 2026, due to their ability to target underlying inflammatory pathways associated with chronic gastrointestinal disorders, particularly inflammatory bowel diseases. Unlike conventional therapies that primarily focus on symptom control, biologics provide long-term disease management and improved clinical outcomes, leading to widespread adoption among healthcare providers. A notable example includes Humira, which has been extensively used for the treatment of Crohn’s disease and ulcerative colitis, demonstrating the significant role biologic therapies play in modern gastroenterology treatment strategies.

Biologics/Biosimilars are also likely to represent the fastest-growing segment, supported by increasing adoption of advanced therapies and the expanding availability of biosimilar products. Healthcare systems are increasingly recognizing the clinical benefits of biologics in managing moderate-to-severe gastrointestinal conditions that may not respond adequately to traditional medications. For example, Remicade and its biosimilar alternatives, which have gained substantial adoption for the management of inflammatory bowel diseases and continue to drive growth across the gastroenterology therapeutics landscape.

Disease Type Insights

The inflammatory bowel disease (IBD) segment is projected to lead the market, capturing around 42% of the revenue share in 2026, supported by the chronic and progressive nature of conditions such as Crohn’s disease and ulcerative colitis, which often require long-term treatment, continuous monitoring, and recurring healthcare interventions. Growing awareness, earlier diagnosis, and increasing availability of advanced therapies have contributed to higher treatment rates. For instance, Crohn's Disease a chronic inflammatory condition that requires comprehensive and long-term therapeutic management.

Gastroesophageal reflux disease (GERD) is likely to be the fastest-growing disease type due to increasing prevalence across diverse age groups and geographic regions. Lifestyle-related factors such as obesity, sedentary behavior, dietary changes, smoking, and stress have significantly contributed to the growing incidence of acid reflux disorders. A representative example includes gastroesophageal reflux disease, which remains one of the most frequently diagnosed gastrointestinal conditions worldwide and continues to generate growing demand for gastroenterology-related treatments and services.

North America Gastroenterology Market Trends

North America is anticipated to be the leading region, accounting for a market share of 45% in 2026, supported by a high prevalence of gastrointestinal disorders, strong healthcare expenditure, and widespread adoption of advanced diagnostic and therapeutic technologies. The region continues to witness increasing utilization of biologics, biosimilars, AI-assisted endoscopy systems, and minimally invasive gastrointestinal procedures. A notable example includes Boston Scientific, which continues to expand its advanced endoscopy and gastrointestinal intervention portfolio.

U.S. Gastroenterology Market Trends

The U.S. is expected to dominate the regional market, accounting for approximately 85% of the market share in 2026, driven by rising rates of GERD, IBD, colorectal cancer, and obesity-related digestive disorders, which continue to increase demand for specialized care. The country maintains strong adoption of biologics and targeted therapies for chronic gastrointestinal conditions. AI-assisted endoscopy is gaining traction among leading healthcare systems. Expansion of outpatient endoscopy centers is improving patient accessibility. Precision medicine initiatives are supporting personalized treatment approaches.

Canada Gastroenterology Market Trends

Canada is likely to be a significant market for gastroenterology, holding approximately 15% of the market share in 2026, supported by increasing digestive disease prevalence and an aging population. Public healthcare programs continue to support access to gastrointestinal diagnostics and treatment services. Expansion of colorectal cancer screening initiatives is improving early disease detection rates. Hospitals are adopting advanced endoscopic technologies to enhance clinical outcomes. The country is witnessing greater use of biologic therapies for inflammatory bowel diseases.

Europe Gastroenterology Market Trends

Europe is likely to be a significant market for gastroenterology in 2026, due to strong healthcare infrastructure, growing adoption of advanced therapies, and increasing focus on early disease detection. The region is witnessing rising demand for biologics, biosimilars, and minimally invasive gastrointestinal procedures. For example, Olympus, which continues to support European healthcare providers through advanced endoscopy platforms that improve visualization, diagnostic accuracy, and procedural efficiency in gastroenterology settings.

U.K. Gastroenterology Market Trends

The U.K. is likely to be a significant market for gastroenterology, accounting for 30% of Europe market share in 2026, supported by rising digestive disease prevalence. National screening initiatives play a key role in early colorectal cancer detection. The healthcare system is expanding the adoption of innovative gastrointestinal diagnostic technologies. The growing use of biologics is improving outcomes for patients with chronic inflammatory disorders. Digital health integration is supporting more efficient patient monitoring and follow-up care. Clinical research activities remain strong across major academic institutions.

Germany Gastroenterology Market Trends

Germany is anticipated to dominate the regional market, accounting for around 25% of the Europe market share in 2026, due to its advanced healthcare infrastructure and strong medical technology adoption. The country has extensive colorectal cancer screening programs that support early diagnosis. Hospitals continue investing in high-performance endoscopy systems and minimally invasive technologies. Demand for biologics and biosimilars is increasing in inflammatory bowel disease management.

Asia Pacific Gastroenterology Market Trends

The Asia Pacific region is likely to be the fastest-growing region, driven by its expanding healthcare infrastructure, large patient populations, and increasing awareness of digestive health. Rapid urbanization, dietary transitions, and aging demographics are contributing to a rising burden of gastrointestinal disorders across the region. For instance, Fujifilm Medical, which continues to expand advanced endoscopy technologies throughout Asia Pacific, helping healthcare providers improve gastrointestinal disease detection and therapeutic outcomes.

China Gastroenterology Market Trends

China is projected to dominate the regional market, holding around a 39% share of the market in 2026, due to the rising prevalence of digestive diseases, which is increasing demand for specialized healthcare services. The government continues investing in healthcare infrastructure and hospital modernization programs. Adoption of advanced endoscopic technologies is expanding rapidly across major medical centers. Domestic pharmaceutical manufacturers are increasing their focus on biologics and biosimilars. AI-enabled diagnostic systems are gaining greater acceptance in clinical settings.

India Gastroenterology Market Trends

India is expected to emerge as a significant market for gastroenterology, accounting for approximately 15% share in 2026, due to rising awareness, expanding healthcare access, and increasing gastrointestinal disease prevalence. The growing incidence of GERD, liver disorders, and inflammatory bowel diseases is driving treatment demand. Private healthcare providers are investing in advanced endoscopy facilities and specialized digestive care centers. Adoption of biologics and targeted therapies is increasing among tertiary hospitals.

The global gastroenterology market exhibits a moderately fragmented structure, driven by the presence of multinational medical technology companies, specialized gastroenterology service providers, endoscopy manufacturers, and emerging digital health innovators. The market continues to evolve as healthcare systems increasingly prioritize early diagnosis, minimally invasive procedures, biologic therapies, and AI-enabled gastrointestinal diagnostics.

With key leaders, including Boston Scientific, Medtronic, Olympus, Fujifilm Medical, Micro-Tech Endoscopy, GI Alliance, and Gastro Health, the market remains highly innovation-focused and clinically driven. These players compete through technological advancements in endoscopy systems, expansion of biologics and biosimilar-supported treatment pathways, integration of artificial intelligence into diagnostic workflows, and enhancement of patient-centered care models.

Key Industry Developments:

• In June 2026, Mindray introduced its expanded Hepatus Series ultrasound systems, advancing gastroenterology imaging with enhanced liver and abdominal diagnostic capabilities. The upgraded platform includes Hepatus 6 and Hepatus 5 systems designed to improve non-invasive assessment of liver disease through elastography-based imaging and high-precision ultrasound analysis.
• In March 2026, Kauvery Group of Hospitals launched dedicated Gastrointestinal (GI) Bleeding Care Centers across its hospital network in Tamil Nadu and Karnataka to strengthen emergency response for life-threatening digestive tract bleeding conditions. The initiative integrates gastroenterologists, emergency physicians, intensivists, and interventional radiology teams under a structured care pathway to ensure rapid diagnosis, stabilization, and endoscopic or surgical intervention.